has knowledgeable contact person
is related to
Protocols  >  Clinical protocol  >  Recommendations for vaccine...

Recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group

Clinical protocol

In ongoing clinical trials (multipeptide loaded cytokine matured moDC +/- CD40L activation in >60 pat.) we have obtained valuable information with high impact on future DC-trials:

1) the presence of 2% DMSO in the thawed final vaccine has no negative impact on the quantity and quality of induced immune responses; thus thawed DMSO containing vials do not have to be centrifuged, but simply diluted;

2) class I peptide loaded cytokine matured DC induce de novo or expand preexisting CD8+ T cell IFN gamma responses in the majority of melanoma patients (>70%), surprisingly without the need for class II peptide loading for T cell help;

3) a statistical analysis of the whole group of vaccinated melanoma patients showed statistically significant DC induced responses towards the antigens gp100.A2, NY-ESO1.A2, MAGE-3.DR11 and MAGE3.DP4.

This information will help finalizing the recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group.

Protocol Steps:
Recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group Graph


created over 9 years ago (2 March 2009)    last modified over 6 years ago (28 September 2011)   [ RDF Rdf ]   [ RelFinder Relfinder ]